Meet The Professors

Dr Judy Garber from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent data with PARP inhibitors for breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPARPBreast22).

Dr Mark Agulnik from City of Hope in Duarte, California, discusses recent therapeutic advances in soft tissue sarcoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySoftTissue22).

Dr Ajai Chari from the Tisch Cancer Institute Clinical Trials Office in New York discusses recent therapeutic advances in multiple myeloma presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMM22).

Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent therapeutic advances in myeloproliferative neoplasms presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMPN22).

Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses recent therapeutic advances in Hodgkin and non-Hodgkin lymphomas. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHLymphoma22).

Dr Andrew Brunner from the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, discusses updates from ASH 2021 on the management of acute myeloid leukemia and myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHAMLMDS22).

Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses current issues in the research and management of localized estrogen receptor-positive breast cancer.   CME information and select publications here (http://www.researchtopractice.com/OncologyTodayERLocalizedBC22).

Dr Peter Hillmen from the University of Leeds in Leeds, England, discusses recent advances in the management of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCLL21/Issue2).

Dr Matthew Davids from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in chronic lymphocytic leukemia presented at ASH 2021. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHCLL22).

Dr Saad Zafar Usmani from the Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent therapeutic advances in transplant-ineligible newly diagnosed multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMMElderly22).

Dr Evan Yu from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses recent therapeutic advances in metastatic castration-resistant prostate cancer CME information and select publications here (http://www.researchtopractice.com/OncologyTodaymCRPC21/Issue2).

Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses recent therapeutic advances in the management of colorectal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCRCANAL21/Issue2).

Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPancreasPARP21).

Dr Alan Bryce from the Mayo Clinic in Phoenix, Arizona, discusses current practice patterns and recent advances in the management of metastatic castration-resistant prostate cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaymCRPC21/Issue1).

Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center discusses recent advances and future directions for the management of early-stage and advanced colorectal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCRCAnal21/Issue1).

Dr Bradley Monk from the University of Arizona College of Medicine in Phoenix discusses the management of advanced ovarian cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarian21).

Dr Gregory Riely from the Memorial Sloan Kettering Cancer Center in New York City discusses recent advances and future directions in the management of patients with NSCLC and EGFR exon 20 insertion mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCEGFR21).

Dr Adil Daud from the UCSF Helen Diller Family Comprehensive Cancer Center discusses recent advances and future directions in the use of immunotherapy for the management of wild-type and BRAF-mutant melanoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMelanomaImmuno21).

Dr Andrew Evens from the Rutgers Cancer Institute in New Jersey discusses the management of newly diagnosed and advanced Hodgkin lymphoma in younger and older patients. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHL21).

Dr Matthew Powell from the Washington University School of Medicine in St Louis, Missouri, discusses therapeutic advances and novel investigational strategies for the management of endometrial cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEndometrial21).